Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Almirall splits chairman and CEO roles

This article was originally published in Scrip

Executive Summary

The Spanish pharmaceutical company Almirall has appointed Eduardo Sanchiz, currently its chief executive of corporate development and finance, its new CEO. Mr Sanchiz will take up the position on 1 July. The move comes after the firm's current CEO and chairman, Jorge Gallardo, proposed to the board that these two roles be separated. Mr Sanchiz took up his current post at Almirall in 2004 after serving 22 years at Lilly working in a variety of roles in finance, marketing, business development and general management. Mr Gallardo was appointed the firm's CEO in 1997 and then chairman and CEO in 2001. He will continue as executive chairman.

You may also be interested in...



Joint Tendering Creates ‘Attractive Nordic Market’

Joint tendering among Nordic countries can help reduce shortages of older, off-patent medicines. 

ATMPs Put EU Cross-Border Healthcare On The Map

Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.

Scotland Recommends Interim Funding For Regeneron/Sanofi’s Libtayo

Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.

Related Companies

UsernamePublicRestriction

Register

SC012328

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel